These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 34304950)

  • 21. Nothing really changed: Arizona patient experience of methadone and buprenorphine access during COVID.
    Meyerson BE; Bentele KG; Russell DM; Brady BR; Downer M; Garcia RC; Garnett I; Lutz R; Mahoney A; Samorano S; Arredondo C; Andres HJ; Coles H; Granillo B
    PLoS One; 2022; 17(10):e0274094. PubMed ID: 36282806
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Experiences with substance use disorder treatment during the COVID-19 pandemic: Findings from a multistate survey.
    Saloner B; Krawczyk N; Solomon K; Allen ST; Morris M; Haney K; Sherman SG
    Int J Drug Policy; 2022 Mar; 101():103537. PubMed ID: 34871945
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Association Between Increased Dispensing of Opioid Agonist Therapy Take-Home Doses and Opioid Overdose and Treatment Interruption and Discontinuation.
    Gomes T; Campbell TJ; Kitchen SA; Garg R; Bozinoff N; Men S; Tadrous M; Munro C; Antoniou T; Werb D; Wyman J
    JAMA; 2022 Mar; 327(9):846-855. PubMed ID: 35230394
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Critical incidents in Colorado's opioid treatment programs: A comparison of the COVID-19 pandemic to previous years.
    Bortz C; Armistead I; Bonaguidi A; Coyle DT
    J Subst Use Addict Treat; 2024 Jun; 161():209342. PubMed ID: 38513975
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Spatial access to opioid treatment program and alcohol and cannabis outlets: analysis of missed doses of methadone during the first, second, and third 90 days of treatment.
    Amiri S; Lutz RB; McDonell MG; Roll JM; Amram O
    Am J Drug Alcohol Abuse; 2020; 46(1):78-87. PubMed ID: 31237791
    [No Abstract]   [Full Text] [Related]  

  • 26. Re-thinking patient stability for methadone in opioid treatment programs during a global pandemic: Provider perspectives.
    Hatch-Maillette MA; Peavy KM; Tsui JI; Banta-Green CJ; Woolworth S; Grekin P
    J Subst Abuse Treat; 2021 May; 124():108223. PubMed ID: 33342667
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clients' experiences on North America's first take-home injectable opioid agonist treatment (iOAT) program: a qualitative study.
    Oviedo-Joekes E; Dobischok S; Carvajal J; MacDonald S; McDermid C; Klakowicz P; Harrison S; LaJeunesse J; Chow N; Brown M; Gill S; Schechter M
    BMC Health Serv Res; 2023 May; 23(1):553. PubMed ID: 37237256
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluating interventions to facilitate opioid agonist treatment access among people who inject drugs in Toronto, Ontario during COVID-19 pandemic restrictions.
    Bouck Z; Scheim AI; Gomes T; Ling V; Caudarella A; Werb D
    Int J Drug Policy; 2022 Jun; 104():103680. PubMed ID: 35447476
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Patient experiences of COVID-19-induced changes to methadone treatment in a large community-based opioid treatment program in Baltimore.
    Abidogun TM; Cole TO; Massey E; Kleinman M; Greenblatt AD; Seitz-Brown CJ; Magidson JF; Belcher AM
    J Subst Use Addict Treat; 2023 Feb; 145():208946. PubMed ID: 36880915
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Patient experiences of methadone treatment changes during the first wave of COVID-19: a national community-driven survey.
    Brothers S; Palayew A; Simon C; Coulter A; Strichartz K; Voyles N; Vincent L
    Harm Reduct J; 2023 Mar; 20(1):31. PubMed ID: 36894968
    [TBL] [Abstract][Full Text] [Related]  

  • 31. "Sign Me Up": a qualitative study of video observed therapy (VOT) for patients receiving expedited methadone take-homes during the COVID-19 pandemic.
    Darnton JB; Bhatraju EP; Beima-Sofie K; Michaels A; Hallgren KA; Soth S; Grekin P; Woolworth S; Tsui JI
    Addict Sci Clin Pract; 2023 Mar; 18(1):21. PubMed ID: 36991506
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Changes to methadone maintenance therapy in the United States, Canada, and Australia during the COVID-19 pandemic: A narrative review.
    Panwala V; Joudrey P; Kowalski M; Bach P; Amram O
    J Subst Use Addict Treat; 2023 Sep; 152():209086. PubMed ID: 37270103
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Take home injectable opioids for opioid use disorder during and after the COVID-19 Pandemic is in urgent need: a case study.
    Oviedo-Joekes E; MacDonald S; Boissonneault C; Harper K
    Subst Abuse Treat Prev Policy; 2021 Mar; 16(1):22. PubMed ID: 33673847
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Methadone dosing at New York State opioid treatment programs following initial revisions to federal regulations.
    Jordan AE; Bachhuber MA; Tuazon E; Jimenez C; Lincourt P; Hussain S; Rubinfeld J; Cunningham CO
    Drug Alcohol Depend; 2024 May; 258():111283. PubMed ID: 38581920
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Racial, Ethnic, and Sex Differences in Methadone-Involved Overdose Deaths Before and After the US Federal Policy Change Expanding Take-home Methadone Doses.
    Harris RA; Long JA; Bao Y; Mandell DS
    JAMA Health Forum; 2023 Jun; 4(6):e231235. PubMed ID: 37294585
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A chance to do it better: Methadone maintenance treatment in the age of Covid-19.
    Frank D
    J Subst Abuse Treat; 2021 Apr; 123():108246. PubMed ID: 33612189
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Increased distance was associated with lower daily attendance to an opioid treatment program in Spokane County Washington.
    Amiri S; Lutz R; Socías ME; McDonell MG; Roll JM; Amram O
    J Subst Abuse Treat; 2018 Oct; 93():26-30. PubMed ID: 30126538
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Three-year retention in methadone opioid agonist treatment: A survival analysis of clients by dose, area deprivation, and availability of alcohol and cannabis outlets.
    Amiri S; Hirchak K; Lutz R; McDonell MG; McPherson SM; Roll JM; Amram O
    Drug Alcohol Depend; 2018 Dec; 193():63-68. PubMed ID: 30340146
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Improving methadone access for rural communities in the USA: lessons learned from COVID-19 adaptations and international models of care.
    Lister JJ; Lister HH
    Rural Remote Health; 2021 Nov; 21(4):6770. PubMed ID: 34757760
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Synthesising evidence of the effects of COVID-19 regulatory changes on methadone treatment for opioid use disorder: implications for policy.
    Krawczyk N; Rivera BD; Levin E; Dooling BCE
    Lancet Public Health; 2023 Mar; 8(3):e238-e246. PubMed ID: 36841564
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.